Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | CTRC | Q99895 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22789194 | 0.75 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL4305603 | 0.75 | NQO1 (0.40) | POLBTDP1L3MBTL1CTRCATM | |
| SCHEMBL22789301 | 0.73 | — | — | |
| SCHEMBL5158885 | 0.73 | — | — | |
| SCHEMBL22775108 | 0.72 | GLA (0.45) | POLBTDP1L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL31265930 | 0.72 | KDM4E (0.36) | POLBTDP1L3MBTL1CTRCKDM4E | |
| SCHEMBL31266031 | 0.72 | KDM4E (0.36) | POLBTDP1L3MBTL1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL22774380 | 0.71 | — | — | |
| SCHEMBL5161464 | 0.71 | — | — | |
| SCHEMBL10525390 | 0.71 | POLB (0.35) | POLBTDP1L3MBTL1ATMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4359382-A1 | TWO-STEP SYNTHESIS OF PYRROLE COMPOUNDS FROM FURAN COMPOUNDS | Chevron Phillips Chemical Company LP (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117881658-A | Two-step synthesis of pyrrole compounds from furan compounds | 切弗朗菲利浦化学公司 | 2024-04-12 | — | — | CN | disclosed |
| US-11608317-B2 | Two-step synthesis of pyrrole compounds from furan compounds | CHEVRON PHILLIPS CHEMICAL COMPANY, LP (US) | 2023-03-21 | — | — | US | disclosed |
| WO-2022197944-A1 | TWO-STEP SYNTHESIS OF PYRROLE COMPOUNDS FROM FURAN COMPOUNDS | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2022-09-22 | — | — | WO | disclosed |
| US-20220298109-A1 | TWO-STEP SYNTHESIS OF PYRROLE COMPOUNDS FROM FURAN COMPOUNDS | CHEVRON PHILLIPS CHEMICAL COMPANY LP | 2022-09-22 | — | — | US | disclosed |
| US-20110178101-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178101-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | REN, AGTR1, AGTR2 | POLB 4101/4885TDP1 2099/4885L3MBTL1 4668/4885 |
| US-11608317-B2 | Two-step synthesis of pyrrole compounds from furan compounds | DDC, DHPS, ACMSD | POLB 753/4885TDP1 3644/4885L3MBTL1 4870/4885 |
| US-20220298109-A1 | TWO-STEP SYNTHESIS OF PYRROLE COMPOUNDS FROM FURAN COMPOUNDS | DDC, DHPS, ACMSD | POLB 753/4885TDP1 3644/4885L3MBTL1 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.